Selective FKBP51 ligands for treatment of psychiatric disorders

US10246413B2 · kind B2 · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Steffen Gaali · Munich, DE
• Felix Hausch · Munich, DE
• Alexander Kirschner · Munich, DE
• Xixi Feng · Munich, DE
• Andreas Bracher · Munich, DE
• Gerd Ruehter · Hamburg, DE

Key dates

• Filing date: Sep 13, 2017
• Grant date: Apr 2, 2019
• Expiry date: Sep 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.